Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
5.44
+0.30 (5.95%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Iovance Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 263.5 | 164.07 | 1.19 | - | - | Upgrade
|
| Revenue Growth (YoY) | 60.60% | 13698.99% | - | - | - | Upgrade
|
| Cost of Revenue | 173.18 | 93.25 | 1.03 | - | - | Upgrade
|
| Gross Profit | 90.32 | 70.82 | 0.16 | - | - | Upgrade
|
| Selling, General & Admin | 152.32 | 152.27 | 106.1 | 104.1 | 83.66 | Upgrade
|
| Research & Development | 300.27 | 276.23 | 333.19 | 294.78 | 259.04 | Upgrade
|
| Operating Expenses | 488.53 | 466.1 | 460.72 | 398.88 | 342.7 | Upgrade
|
| Operating Income | -398.21 | -395.28 | -460.56 | -398.88 | -342.7 | Upgrade
|
| Interest & Investment Income | 3.11 | 4.51 | 9.44 | 3.46 | 6.46 | Upgrade
|
| EBT Excluding Unusual Items | -395.11 | -390.77 | -451.12 | -395.42 | -336.24 | Upgrade
|
| Merger & Restructuring Charges | -5.14 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 7.2 | 10.26 | 3.61 | -0.47 | -6.01 | Upgrade
|
| Other Unusual Items | - | 5.5 | - | - | - | Upgrade
|
| Pretax Income | -393.05 | -375.01 | -447.52 | -395.89 | -342.25 | Upgrade
|
| Income Tax Expense | -2.07 | -2.83 | -3.48 | - | - | Upgrade
|
| Net Income | -390.98 | -372.18 | -444.04 | -395.89 | -342.25 | Upgrade
|
| Net Income to Common | -390.98 | -372.18 | -444.04 | -395.89 | -342.25 | Upgrade
|
| Shares Outstanding (Basic) | 357 | 290 | 235 | 159 | 153 | Upgrade
|
| Shares Outstanding (Diluted) | 357 | 290 | 235 | 159 | 153 | Upgrade
|
| Shares Change (YoY) | 23.28% | 23.28% | 47.64% | 3.82% | 10.92% | Upgrade
|
| EPS (Basic) | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 | Upgrade
|
| EPS (Diluted) | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 | Upgrade
|
| Free Cash Flow | -336.24 | -364.05 | -384.11 | -313.18 | -265.52 | Upgrade
|
| Free Cash Flow Per Share | -0.94 | -1.26 | -1.63 | -1.97 | -1.73 | Upgrade
|
| Gross Margin | 34.28% | 43.17% | 13.12% | - | - | Upgrade
|
| Operating Margin | -151.12% | -240.92% | -38734.99% | - | - | Upgrade
|
| Profit Margin | -148.38% | -226.84% | -37345.42% | - | - | Upgrade
|
| Free Cash Flow Margin | -127.61% | -221.89% | -32305.30% | - | - | Upgrade
|
| EBITDA | -362.27 | -357.64 | -439.14 | -389.57 | -339.59 | Upgrade
|
| EBITDA Margin | -137.48% | -217.98% | - | - | - | Upgrade
|
| D&A For EBITDA | 35.94 | 37.63 | 21.42 | 9.31 | 3.11 | Upgrade
|
| EBIT | -398.21 | -395.28 | -460.56 | -398.88 | -342.7 | Upgrade
|
| EBIT Margin | -151.12% | -240.92% | - | - | - | Upgrade
|
| Revenue as Reported | 263.5 | 164.07 | 1.19 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.